Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial

Proxalutamide study #6 of 7 All Outcomes

7/10 Early treatment study

Cadegiani et al., medRxiv, doi:10.1101/2021.07.06.21260086 (Preprint)
Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial

Source PDF Share Tweet

RCT 177 women in Brazil, 75 treated with proxalutamide, showing significantly lower hospitalization with treatment.

Cadegiani et al., 7/10/2021, Double Blind Randomized Controlled Trial, Brazil, South America, preprint, 7 authors.

risk of death, 63.4% lower, RR 0.37, p = 1.00, treatment 0 of 75 (0.0%), control 1 of 102 (1.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).

risk of mechanical ventilation, 89.7% lower, RR 0.10, p = 0.07, treatment 0 of 75 (0.0%), control 5 of 102 (4.9%), continuity correction due to zero event (with reciprocal of the contrasting arm).

risk of hospitalization, 85.7% lower, RR 0.14, p < 0.001, treatment 2 of 75 (2.7%), control 19 of 102 (18.6%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 7 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit